Eléments de l'association
|  |
List of bibliographic references
Number of relevant bibliographic references: 6.| Ident. | Authors (with country if any) | Title |
|---|---|---|
| 002B38 | M. Takeno ; H. Ideguchi ; A. Suda ; R. Watanabe ; H. Kikuchi [Japon] ; H. Nagafuchi ; M. Kuwana [Japon] ; K. Saito ; S. Hirohata ; Y. Ishigatsubo [Japon] | SAT0159 Clinical Features of Japanese Patients with Vasculo- BehÇEt’S Disease: A Multicenter Study by BehÇEt’S Disease Research Committee, MHLW |
| 002B48 | Y. Yabe [Japon] ; T. Kojima ; A. Kaneko ; Y. Kanayama ; Y. Hirano ; T. Shioura ; K. Saito [Japon] ; N. Asai ; T. Kobayakawa ; N. Ishiguro | SAT0143 Analysis of Patients Who Obtained Remission by Disease Activity Score After Tocilizumab Treatment But Still had Low Disease Activity by Clinical Disease Activity Index, and Examination of Points for Treatment Intensification |
| 003067 | Y. Yabe [Japon] ; T. Kojima ; A. Kaneko ; Y. Kanayama ; T. Shioura ; N. Asai ; T. Kobayakawa ; K. Saito [Japon] ; N. Ishiguro | AB0590 Rates of treatment continuation and remission in 97 patients with high c-reactive protein receiving tocilizumab: 2-year study based on the tsurumai biologics communication registry |
| 003071 | Y. Tanaka ; T. Takeuchi [Japon] ; K. Amano ; E. Sato [Japon] ; M. Nawata ; H. Nagasawa ; D. Hoshi [Japon] ; K. Saito ; S. Fukuyo ; K. Hanami ; H. Kameda [Japon] ; T. Kurasawa ; Y. Kaneko [Japon] ; H. Yamanaka [Japon] | AB0586 104-weeks assessments of clinical and structural remission in rheumatoid arthritis patients with tocilizumab from the reaction study |
| 003092 | N. Asai ; T. Kobayakawa ; K. Saito ; T. Shioura ; Y. Yabe [Japon] ; T. Kojima ; A. Kaneko [Japon] ; N. Ishiguro | AB0564 Continuation and remission rates of tocilizumab treatment based on improvement in patient global assessment: 2-year study based on the tsurumai biologics communication registry |
| 003185 | Y. Yabe [Japon] ; T. Kojima ; A. Kaneko ; Y. Kanayama ; Y. Hirano ; T. Shioura ; K. Saito [Japon] ; N. Asai ; T. Kobayakawa ; N. Ishiguro | AB0338 Evaluation of tocilizumab treatment continuation rate stratified by time of start of administration |
| This area was generated with Dilib version V0.6.34. |  |